Biomerica Inc (BMRA) stock
BMRANasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends May 31
Financials through Q1 FY2027, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 15, 2026Score 8/3049% below fair value
$1.24−0.08 (-6.44%)
Close on Nov 17, 2026Market cap $5.68MP/E –Yield –
Biomerica r&d expenses
Research and development expenses are spending on new products and technology.
Biomerica's R&D Expenses for the twelve months ending Aug 31, 2026 was $782.00K, down 16.6% year over year. For fiscal 2026 it was $788.00K, down 23.0% from the year before. Over ten years it grew 0.1% a year on average. The highest annual figure on record is $2.19M in fiscal 2021.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | May 31, 2026 | $788.00K | -23.0% |
| FY2025 | May 31, 2025 | $1.02M | -31.4% |
| FY2024 | May 31, 2024 | $1.49M | -5.9% |
| FY2023 | May 31, 2023 | $1.58M | -12.6% |
| FY2022 | May 31, 2022 | $1.81M | -17.4% |
| FY2021 | May 31, 2021 | $2.19M | +13.6% |
| FY2020 | May 31, 2020 | $1.93M | +15.1% |
| FY2019 | May 31, 2019 | $1.68M | +20.1% |
| FY2018 | May 31, 2018 | $1.40M | +23.7% |
| FY2017 | May 31, 2017 | $1.13M | +44.9% |
| FY2016 | May 31, 2016 | $780.33K | +6.4% |
| FY2015 | May 31, 2015 | $733.64K | +24.4% |
| FY2014 | May 31, 2014 | $589.87K | +28.5% |
| FY2013 | May 31, 2013 | $459.09K | +32.3% |
| FY2012 | May 31, 2012 | $347.13K | -17.5% |
| FY2011 | May 31, 2011 | $420.57K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ3 2026 | Aug 31, 2026 | $206.00K | -2.8% |
| Q4 FY2026CQ2 2026 | May 31, 2026 | $205.00K | -18.7% |
| Q3 FY2026CQ1 2026 | Feb 28, 2026 | $178.00K | -18.0% |
| Q2 FY2026CQ4 2025 | Nov 30, 2025 | $193.00K | -24.9% |
| Q1 FY2026CQ3 2025 | Aug 31, 2025 | $212.00K | -28.6% |
| Q4 FY2025CQ2 2025 | May 31, 2025 | $252.00K | -4.9% |
| Q3 FY2025CQ1 2025 | Feb 28, 2025 | $217.00K | -36.7% |
| Q2 FY2025CQ4 2024 | Nov 30, 2024 | $257.00K | -37.6% |
| Q1 FY2025CQ3 2024 | Aug 31, 2024 | $297.00K | -37.1% |
| Q4 FY2024CQ2 2024 | May 31, 2024 | $265.00K | -28.2% |
| Q3 FY2024CQ1 2024 | Feb 29, 2024 | $343.00K | -12.5% |
| Q2 FY2024CQ4 2023 | Nov 30, 2023 | $412.00K | -10.8% |
| Q1 FY2024CQ3 2023 | Aug 31, 2023 | $472.00K | +30.7% |
| Q4 FY2023CQ2 2023 | May 31, 2023 | $369.00K | -25.5% |
| Q3 FY2023CQ1 2023 | Feb 28, 2023 | $392.00K | +1.3% |
| Q2 FY2023CQ4 2022 | Nov 30, 2022 | $462.00K | -15.7% |
| Q1 FY2023CQ3 2022 | Aug 31, 2022 | $361.00K | -5.4% |
| Q4 FY2022CQ2 2022 | May 31, 2022 | $495.42K | +63.8% |
| Q3 FY2022CQ1 2022 | Feb 28, 2022 | $387.10K | -31.4% |
| Q2 FY2022CQ4 2021 | Nov 30, 2021 | $547.93K | -11.1% |
| Q1 FY2022CQ3 2021 | Aug 31, 2021 | $381.54K | -46.4% |
| Q4 FY2021CQ2 2021 | May 31, 2021 | $302.43K | -55.8% |
| Q3 FY2021CQ1 2021 | Feb 28, 2021 | $563.97K | +19.2% |
| Q2 FY2021CQ4 2020 | Nov 30, 2020 | $616.56K | +52.3% |
| Q1 FY2021CQ3 2020 | Aug 31, 2020 | $711.51K | +92.1% |
| Q4 FY2020CQ2 2020 | May 31, 2020 | $683.97K | +67.3% |
| Q3 FY2020CQ1 2020 | Feb 29, 2020 | $473.28K | -4.8% |
| Q2 FY2020CQ4 2019 | Nov 30, 2019 | $404.85K | +6.1% |
| Q1 FY2020CQ3 2019 | Aug 31, 2019 | $370.47K | -5.4% |
| Q4 FY2019CQ2 2019 | May 31, 2019 | $408.81K | -15.5% |
| Q3 FY2019CQ1 2019 | Feb 28, 2019 | $497.10K | +40.6% |
| Q2 FY2019CQ4 2018 | Nov 30, 2018 | $381.41K | +40.0% |
| Q1 FY2019CQ3 2018 | Aug 31, 2018 | $391.78K | +35.8% |
| Q4 FY2018CQ2 2018 | May 31, 2018 | $483.79K | +38.7% |
| Q3 FY2018CQ1 2018 | Feb 28, 2018 | $353.56K | +37.7% |
| Q2 FY2018CQ4 2017 | Nov 30, 2017 | $272.44K | -9.5% |
| Q1 FY2018CQ3 2017 | Aug 31, 2017 | $288.59K | – |
| Q4 FY2017CQ2 2017 | May 31, 2017 | $348.71K | – |
| Q3 FY2017CQ1 2017 | Feb 28, 2017 | $256.72K | – |
| Q2 FY2017CQ4 2016 | Nov 30, 2016 | $300.96K | – |
See a number that looks wrong?